Legend Biotech Corporation (LEGN) — Analyst outlook / Analyst consensus target is. Based on 19 analyst ratings, the consensus is bullish — 16 Buy, 3 Hold.
The consensus price target is $58.60 (low: $24.00, high: $75.00), representing an upside of 213.5% from the current price $18.69.
Analysts estimate Earnings Per Share (EPS) of $-0.84 and revenue of $0.62B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.94 vs est $-0.84 (missed -131%). 2025: actual $-1.60 vs est $-0.79 (missed -102.2%). Analyst accuracy: 46%.
LEGN Stock — 12-Month Price Forecast
$58.60
▲ +213.54% Upside
Average Price Target
Based on 19 Wall Street analysts offering 12-month price targets for Legend Biotech Corporation, the average price target is $58.60, with a high forecast of $75.00, and a low forecast of $24.00.
The average price target represents a +213.54% change from the last price of $18.69.
Highest Price Target
$75.00
Average Price Target
$58.60
Lowest Price Target
$24.00
LEGN Analyst Ratings
Buy
Based on 19 analysts giving stock ratings to Legend Biotech Corporation in the past 3 months
EPS Estimates — LEGN
46%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.94
vs Est –$0.84
▼ 56.7% off
2025
Actual –$1.60
vs Est –$0.79
▼ 50.5% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — LEGN
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.627B
vs Est $0.621B
▲ 1.1% off
2025
Actual $1.032B
vs Est $1.030B
▲ 0.1% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
